OX40 (CD134) and OX40L
- PMID: 19760068
- DOI: 10.1007/978-0-387-89520-8_6
OX40 (CD134) and OX40L
Abstract
The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. While OX40 is expressed predominantly on T-lymphocytes early after antigen activation, OX40L is expressed on activated antigen presenting cells and endothelial cells within acute inflammatory environments. We discuss here how ligation of OX40 by OX40L leads to enhanced T-cell survival, along with local inflammatory responses that appear critical for both effective T-cell mediated responses and chronic immune pathologies. We describe how interventions that block or mimic the OX40-OX40L interaction can be applied to treat autoimmune diseases or enhance anti-tumor immune responses. The clinically relevant properties of these agents emphasize the importance of this particular TNFSF-TNFSF in health and disease.
Similar articles
-
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.Crit Rev Immunol. 2007;27(5):415-36. doi: 10.1615/critrevimmunol.v27.i5.20. Crit Rev Immunol. 2007. PMID: 18197805 Review.
-
OX40, OX40L and Autoimmunity: a Comprehensive Review.Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32. doi: 10.1007/s12016-015-8498-3. Clin Rev Allergy Immunol. 2016. PMID: 26215166 Review.
-
OX40/OX40L axis: not a friend in autoimmunity.Oncotarget. 2015 Sep 8;6(26):21779-80. doi: 10.18632/oncotarget.4973. Oncotarget. 2015. PMID: 26314852 Free PMC article. No abstract available.
-
OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.Adv Immunol. 2010;105:63-98. doi: 10.1016/S0065-2776(10)05003-0. Adv Immunol. 2010. PMID: 20510730 Review.
-
Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.Hum Immunol. 2007 Jul;68(7):563-71. doi: 10.1016/j.humimm.2007.03.012. Epub 2007 Apr 13. Hum Immunol. 2007. PMID: 17584577
Cited by
-
A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.PLoS One. 2013;8(2):e56539. doi: 10.1371/journal.pone.0056539. Epub 2013 Feb 11. PLoS One. 2013. PMID: 23409193 Free PMC article.
-
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Oncoimmunology. 2017. PMID: 29209572 Free PMC article. Review.
-
Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients, part II: omics analyses of urine and blood samples.Clin Kidney J. 2017 Feb;10(1):106-115. doi: 10.1093/ckj/sfw077. Epub 2016 Sep 6. Clin Kidney J. 2017. PMID: 28643819 Free PMC article. Review.
-
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy.Molecules. 2024 Jan 17;29(2):454. doi: 10.3390/molecules29020454. Molecules. 2024. PMID: 38257366 Free PMC article. Review.
-
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.Nat Commun. 2014 Jun 24;5:4229. doi: 10.1038/ncomms5229. Nat Commun. 2014. PMID: 24957461 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical